Next generation of immune checkpoint therapy in cancer: new developments and challenges
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Authors
Keywords
Cancer, Immunotherapy, Tumor microenvironment, Immune evasion, Cytotoxic T lymphocytes, Immunotherapy, Immune checkpoint therapy, Co-stimulatory pathways, Inhibitory pathways, Tumor microenvironment
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-03-15
DOI
10.1186/s13045-018-0582-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Cancer immunotherapy beyond immune checkpoint inhibitors
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- Cancer immunotherapy targeting the CD47/SIRPα axis
- (2017) Kipp Weiskopf EUROPEAN JOURNAL OF CANCER
- LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment
- (2017) Baldur Sveinbjørnsson et al. Future Medicinal Chemistry
- Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results
- (2017) M. Bagot et al. HEMATOLOGICAL ONCOLOGY
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Modulation of cancer-specific immune responses by amino acid degrading enzymes
- (2017) Elina Timosenko et al. Immunotherapy
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
- (2017) Kai Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Is CD47 an innate immune checkpoint for tumor evasion?
- (2017) Xiaojuan Liu et al. Journal of Hematology & Oncology
- OX40: Structure and function – What questions remain?
- (2017) Jane Willoughby et al. MOLECULAR IMMUNOLOGY
- Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
- (2017) Xiuwen Lan et al. OncoTargets and Therapy
- Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas
- (2017) Christian Schmitt et al. Frontiers in Immunology
- Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
- (2017) Mariona Cabo et al. OncoImmunology
- Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment
- (2017) David Gyori et al. Cancers
- 4-1BB agonism: adding the accelerator to cancer immunotherapy
- (2016) Cariad Chester et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
- (2016) Rachel E. Sanborn et al. CANCER RESEARCH
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
- (2016) T Yamazaki et al. CELL DEATH AND DIFFERENTIATION
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
- (2016) Y. Lou et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
- (2016) E. Picarda et al. CLINICAL CANCER RESEARCH
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.
- (2016) Nathan Bahary et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy
- (2016) Hui Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging therapeutic agents for lung cancer
- (2016) Bhagirathbhai Dholaria et al. Journal of Hematology & Oncology
- Application potential of toll-like receptors in cancer immunotherapy
- (2016) Ming Shi et al. MEDICINE
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The oncolytic peptide LTX-315 triggers immunogenic cell death
- (2016) H Zhou et al. Cell Death & Disease
- Abstract A101: Role of TIM-3/Galectin-9 pathway in lung cancer
- (2016) Yoshihiro Ohue et al. Cancer Immunology Research
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- Journal for immunotherapy of cancer reviewer acknowledgement 2015
- (2016) Pedro Romero Journal for ImmunoTherapy of Cancer
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
- (2015) Taofeek Kunle Owonikoko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
- (2015) Z. Sun et al. CANCER RESEARCH
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential
- (2015) Koen van de Ven et al. Immunotherapy
- Interleukin 10 (IL-10)-mediated Immunosuppression
- (2015) Sharad K. Mittal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
- (2015) Miguel F. Sanmamed et al. SEMINARS IN ONCOLOGY
- Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
- (2015) Carin I. M. Dahlberg et al. Frontiers in Immunology
- The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+T cell responses
- (2015) Robert J Johnston et al. OncoImmunology
- IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
- (2015) Jakub Tomala et al. OncoImmunology
- Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
- (2015) John Powderly et al. Journal for ImmunoTherapy of Cancer
- Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
- (2015) Christopher Harvey et al. Journal for ImmunoTherapy of Cancer
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
- (2015) Stefanie N. Linch et al. Frontiers in Oncology
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection
- (2014) J. V. Gorman et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
- (2014) Ulrich H. Weidle et al. SEMINARS IN ONCOLOGY
- Killer Immunoglobulin-like Receptors and Tumor Immunity
- (2014) D. M. Benson et al. Cancer Immunology Research
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
- (2014) J. L. Lines et al. Cancer Immunology Research
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- The expression and modulation of CEACAM1 and tumor cell transformation
- (2013) Valentina Fiori et al. ANNALI DELL ISTITUTO SUPERIORE DI SANITA
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Molecular Pathways: Targeting the TGF- Pathway for Cancer Therapy
- (2012) A. L. Smith et al. CLINICAL CANCER RESEARCH
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
- (2012) Andrea Wang-Gillam et al. INVESTIGATIONAL NEW DRUGS
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression
- (2011) Michael K. Wendt et al. CELL AND TISSUE RESEARCH
- Melanoma drug wins US approval
- (2011) Heidi Ledford NATURE
- CD73: A Novel Target for Cancer Immunotherapy
- (2010) B. Zhang CANCER RESEARCH
- Putting the brakes on BTLA in T cell–mediated cancer immunotherapy
- (2010) Chrystal M. Paulos et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
- (2010) K. Takeda et al. JOURNAL OF IMMUNOLOGY
- Role of CD27/CD70 pathway of activation in immunity and tolerance
- (2010) Julie Denoeud et al. JOURNAL OF LEUKOCYTE BIOLOGY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer
- (2010) D. Miotto et al. LUNG CANCER
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines
- (2009) Javier G. Casado et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
- (2009) Kim Kramer et al. JOURNAL OF NEURO-ONCOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- Roles of TGFβ in metastasis
- (2008) David Padua et al. CELL RESEARCH
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started